PVLA compared with ARQT: revenue, margins and what each company keeps, and the suppliers and customers both name

PVLAPalvella Therapeutics, Inc.

Mkt capRevenueRevenue

ARQTArcutis Biotherapeutics, Inc.

Mkt capRevenueRevenue

Compare

PVLAPalvella Therapeutics, Inc.

ARQTArcutis Biotherapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

PVLA

2 of 3at or beyond implied

Reportimpliedrealized× implied

Nov 5 '26±8.2%▼−3.35%×0.41

Aug 4 '26—▲+7.96%—

May 7 '26±8.6%▼−12.99%×1.51

Mar 31 '26±11.9%▲+12.64%×1.06

ARQT

2 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±12.3%▼−20.70%×1.68

Q2 FY26±10.2%▼−2.47%×0.25

= impliedPVLA realized, solidARQT realized, hatchedOne scale, both sides: full bar = 28%× = |realized| ÷ impliedspan: PVLA 219d · ARQT 373dSource: market data

Q1 FY26

±13.1%

▲+5.78%

×0.44

Q3 FY25±15.7%▲+27.04%×1.72

PVLAPalvella Therapeutics, Inc.

174.90▲+11.51%· post 174.90

Mkt cap—Revenue—Revenue—

ARQTArcutis Biotherapeutics, Inc.

25.55▼−5.38%· post 25.56

ClosedNov 6 '26

Mkt cap$3.2BRevenue$144MQ3 FY26Revenue$376MFY25

Compare

ClosedNov 6 '26

PVLAPalvella Therapeutics, Inc.

ARQTArcutis Biotherapeutics, Inc.

174.90▲+11.51%post 174.90

Price

25.55▼−5.38%post 25.56

—

Mkt cap

$3.2B

—

Revenue

$144MQ3 FY26

—

Revenue

$376MFY25

PVLA174.90▲+11.51%vsARQT25.55▼−5.38%ClosedNov 6 '26